MRVI — Maravai Lifesciences Holdings Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.18bn
- $2.54bn
- $288.95m
- 78
- 21
- 64
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -5.2 | 78.8 | 469 | 491 | -138 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 4.1 | 17.1 | 4.29 | 16.2 | -628 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.29 | 35.9 | -177 | -45.1 | 97.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 24.1 | 152 | 369 | 536 | 126 |
Capital Expenditures | -17.1 | -25.4 | -14.8 | -17.1 | -65.6 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | 31.5 | 121 | -251 | -56.8 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -17.1 | 6.07 | 106 | -268 | -122 |
Financing Cash Flow Items | -1.53 | -445 | -155 | -184 | -55.3 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -4.17 | 53.2 | -159 | -187 | -61.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.83 | 211 | 315 | 80.9 | -57.2 |